The platform has completed or terminated 12 out of the original 16 R&D studies, either because research objectives were achieved or because the candidate product was unsuitable.
There are 4 ongoing studies:
- One is receiving non-IPA funding: -Virus-Like Particles (VLP) awaiting Phase IIB/III approval
- 3 tanesi pilot üretim için hazır ve IPA’dan sürekli desteğe ihtiyaç duymaktadır.
- DNA aşısı
- Rekombinant spike protein aşısı
- Nötralize Edici Antikorlar ilacı
V5 - DNA Vaccine
Ege University
Total of 22 researchers including 11 women
Achievements
DNA vaccine design
Development of DNA vaccine platform
Production optimization of developed DNA vaccine in bioreactor
GMP production approval obtained from TITCK for DNA vaccine production
Technical Capabilities
Rapid DNA vaccine creation in FDA-approved vector
DNA vaccine application using electroporation method to increase vaccine efficacy
Upstream and downstream process optimization
V2 - Recombinant spike protein vaccine
Izmir Biomedicine and Genome Center
Total of 35 researchers including 17 women
Achievements
RBD-expressing yeast strain was developed
Animal studies were completed
Technology transfer to industry was completed
Technical Capabilities
Application of Genetic Engineering techniques
Experience gained in yeast physiology, fermentation, purification and formulation
Scientific Outputs
1 article was published
Technology transfer files including batch records were transferred to ATABAY BIO
Neutralizing Antibody Drug
TUBITAK - MAM
Total of 50 researchers including 25 women
Achievements
Pre-clinical and stability studies completed for drug neutralizing COVID-19
Technical Capabilities
Recombinant antibody engineering
In vitro neutralization test development
In vivo challenge test
Scientific Outputs
6 articles published
6 publication submissions made
1 review published
2 patent preparations
10 posters
